Kodein Eql Pharma (Codeine Phosphate Hemihydrate)

• Kodein Eql Pharma (codeine) acts on the central nervous system to alleviate pain and reduce cough reflex sensitivity.
• Moderate pain: provides analgesia for conditions such as musculoskeletal injuries or postoperative discomfort.
• Cough suppression: reduces the urge to cough in acute respiratory infections.
• Dental pain: helps control pain after dental procedures.

• Codeine exerts its effects by binding to mu‑opioid receptors in the central nervous system, inhibiting the release of neurotransmitters that transmit pain signals and diminishing the cough reflex through action on the medullary cough center.

Common Side Effects

• Nausea and vomiting
• Constipation
• Drowsiness or sedation
• Dizziness
• Dry mouth
• Light‑headedness

Serious or Rare Side Effects

• Respiratory depression, especially in high doses or when combined with other depressants
• Severe allergic reactions (rash, itching, swelling, difficulty breathing)
• Hypotension or cardiovascular instability
• Dependence or withdrawal syndrome with prolonged use
• Seizures (rare)
• Adrenal insufficiency in chronic high‑dose therapy

Before prescribing Kodein Eql Pharma, clinicians should evaluate patient history and potential risk factors.

• Assess pain level: ensure opioid therapy is appropriate for the severity of pain.
• Age restriction: avoid use in children under 12 years unless specifically indicated.
• Respiratory disorders: use with caution in patients with asthma, COPD, or sleep apnea.
• Concomitant CNS depressants: avoid or closely monitor when combined with alcohol, benzodiazepines, or other sedatives.
• Hepatic impairment: dose adjustment may be required in patients with liver disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Codeine may interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates, alcohol) – increased risk of respiratory depression.
• Monoamine oxidase inhibitors (MAOIs) – risk of severe serotonin syndrome.
• CYP2D6 inhibitors (e.g., fluoxetine, quinidine) – reduced conversion to active metabolite, decreasing analgesic effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine) – may lower plasma concentrations.
• Antihistamines and anticholinergics – additive sedation.
• Diuretics – may enhance hypotensive effects.
• Certain antidepressants (e.g., tricyclics) – increased sedation.
• Antitussives containing dextromethorphan – risk of additive CNS depression.